col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


81 Results       Page 1

 [1] 
Wiley: Alimentary Pharmacology & Therapeutics
  original article Date Title Authors   All Authors
1 [GO] 2024―Apr―01 Review article: Telecare in gastroenterology-Within the COVID-19 pandemic and beyond Fatima Hakak, Rajan N. Patel, Richard B. Gearry
2 [GO] 2023―Sep―05 Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19 Ralley E. Prentice, Doug Tjandra, Mayur Garg, John S. Lubel, Spiros Fourlanos, Doug Johnson, et al. (+2)
3 [GO] 2023―Sep―05 Letter: Covid-19-re-initiating clinical services for chronic gastrointestinal diseases. How and when? Authors' reply Ralley E. Prentice, Aysha H. Al-Ani, Britt Christensen
4 [GO] 2023―Sep―05 Letter: Covid-19-re-initiating clinical services for chronic gastrointestinal diseases. How and when? Edward Britton, Paul Richardson, Ibrahim Mian, Thomas Conley, David Byrne, Holly Boyd, et al. (+4)
5 [GO] 2023―Sep―04 Letter: unknown denominator and misleading conclusions in COVID-19 Manuel Rodríguez-Perálvarez, Magdalena Salcedo, José Antonio Pons, Jordi Colmenero
6 [GO] 2023―Sep―04 Letter: gastrointestinal symptoms pre-admission are associated with greater severity of COVID-19 Jiong Yu, Weiming Xu, Jing Ma, Xinyu Sheng, Xiaowei Shi, Jian Wu, et al. (+4)
7 [GO] 2023―Sep―04 Editorial: intended victim or innocent bystander? The liver in COVID-19 Greg Packer, Mansoor N. Bangash
8 [GO] 2023―Sep―04 Letter: elevated liver enzymes and outcome in COVID-19 Anshuman Elhence, Ramesh Kumar
9 [GO] 2023―Sep―04 Letter: population mortality from COVID-19 and latitude-data from China. Authors' reply Jonathan M Rhodes, Sreedhar Subramanian, Eamon Laird, Rose Anne Kenny
10 [GO] 2023―Sep―04 Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7 808 patients in France Pauline Bataille, Aurélien Amiot, Pascal Claudepierre, Nicolas Paris, Antoine Neuraz, Ivan Lerner, et al. (+7)
11 [GO] 2023―Sep―04 Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7808 patients in France. Authors' reply Carlos Taxonera, Cristina Alba
12 [GO] 2023―Sep―04 Letter: liver involvement and mortality in COVID-19 patients Xiu-He Lv, Jin-Lin Yang, Kai Deng
13 [GO] 2023―Sep―04 Letter: liver involvement and mortality in COVID-19 patients - authors' reply Francesca Romana Ponziani, Fabio Del Zompo, Antonio Nesci, Francesco Santopaolo, Gianluca Ianiro, Antonio Gasbarrini, Maurizio Pompili
14 [GO] 2023―Sep―04 Editorial: intended victim or innocent bystander? The liver in COVID-19-Authors' reply Haijun Huang, Shanshan Chen, Hong Li, Xian-Long Zhou, Yining Dai, Jia Wu, et al. (+7)
15 [GO] 2023―Sep―04 Letter: gastrointestinal symptoms pre-admission are associated with greater severity of COVID-19-authors' reply Yuan Tian, Long Rong
16 [GO] 2023―Sep―04 Letter: unknown denominator and misleading conclusions in Covid-19-authors' reply Isabel Garrido, Rodrigo Liberal, Guilherme Macedo
17 [GO] 2023―Sep―04 Letter: SARS-CoV-2 induced gastrointestinal inflammation-authors' reply Carlos Taxonera, Cristina Alba
18 [GO] 2023―Sep―04 Letter: SARS-CoV-2-induced gastrointestinal inflammation Philipp A. Reuken, Michaela Wüst, Bettina Löffler, Michael Bauer, Andreas Stallmach
19 [GO] 2023―Sep―02 Letter: how frequently does COVID-19 mimic an IBD flare when community transmission of SARS-CoV-2 is active? Neil O’Morain, Carolann Coe, Patrick Mallon, Patrick Twomey, Cillian F. De Gascun, Glen A. Doherty
20 [GO] 2023―Sep―02 Letter: liver involvement and mortality in COVID-19-the role of anti-viral therapy should be considered Lucio Boglione, Roberto Rostagno, Federica Poletti, Roberta Moglia, Bianca Bianchi, Maria Esposito, et al. (+2)
21 [GO] 2023―Sep―02 Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy Giuseppe Privitera, Daniela Pugliese, Franco Scaldaferri, Alessandro Armuzzi
22 [GO] 2023―Sep―02 Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply Aysha H. Al-Ani, Ralley E. Prentice, Clarissa Rentsch, Britt Christensen
23 [GO] 2023―Sep―01 Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study Christopher A. Lamb, Shaji Sebastian, Alexandra J. Kent, Jonathan P. Segal, Haidee A. Gonzalez, Matthew J. Brookes, et al. (+8)
24 [GO] 2023―Aug―12 STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease Simon Woelfel, Joel Dütschler, Marius König, Alex Dulovic, Nicole Graf, Daniel Junker, et al. (+20)
25 [GO] 2023―Jun―25 Editorial: Alcohol-related liver disease is the primary driver of cirrhosis-related hospital admissions in the COVID-19 era-What can be done? Alexandra D. Frolkis, Stephen E. Congly
26 [GO] 2023―May―16 Trends in aetiology-based hospitalisation for cirrhosis before and during the COVID -19 pandemic in the United States Donghee Kim, Brandon J. Perumpail, Karn Wijarnpreecha, Richie Manikat, George Cholankeril, Aijaz Ahmed
27 [GO] 2023―Jan―16 Risk of severe and opportunistic infections and the impact of SARS-COV-2 on this risk in a nationwide cohort of patients with inflammatory bowel disease Nabeel Khan, Nadim Mahmud, Manthankumar Patel, Ramaswamy Sundararajan, Walter Reinisch
28 [GO] 2022―Dec―08 Editorial: immunosuppression and SARS-CoV -2 vaccination-where do we stand? Ashwin N. Ananthakrishnan
29 [GO] 2022―Oct―29 Systemic and T cell-associated responses to SARS-CoV -2 immunisation in gut inflammation ( STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV -2 Simon Woelfel, Joel Dütschler, Marius König, Nicole Graf, Vasileios Oikonomou, Claudia Krieger, et al. (+15)
30 [GO] 2022―Oct―05 Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID -19 pandemic: the PREPARE-IBD multicentre cohort study Aamir Saifuddin, Alexandra J. Kent, Shameer J. Mehta, Lucy C. Hicks, Haidee A. Gonzalez, Jonathan P. Segal, et al. (+272)
31 [GO] 2022―Jun―11 Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID -19 pandemic-authors’ reply Yousaf Hadi, Gursimran S. Kochhar
32 [GO] 2022―May―11 Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID -19 pandemic Wen-Qiang Yuan, Fei Li, Liu-Chan Yang, Zai-Li Yang, De-Jun Cui
33 [GO] 2022―Apr―16 Letter: association between COVID-19 and inflammatory bowel disease Hui-Yuan Chen, Shiow-Ing Wang, Renin Chang, James Cheng-Chung Wei
34 [GO] 2022―Apr―01 Letter: inflammatory bowel disease services during the Covid-19 pandemic Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
35 [GO] 2022―Apr―01 Letter: inflammatory bowel disease services during the Covid-19 pandemic - authors' reply Mohammed Deputy, Ailsa Hart, Omar Faiz
36 [GO] 2022―Mar―31 Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: A systematic review, meta-analysis and meta-regression Abhishek Bhurwal, Hemant Mutneja, Vikas Bansal, Akshay Goel, Shilpa Arora, Bashar Attar, et al. (+5)
37 [GO] 2022―Feb―08 The use of, and outcomes for, inflammatory bowel disease services during the Covid-19 pandemic: a nationwide observational study Mohammed Deputy, Kapil Sahnan, Guy Worley, Komal Patel, Violeta Balinskaite, Alex Bottle, et al. (+4)
38 [GO] 2021―Dec―14 Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis Yousaf Hadi, Parambir S. Dulai, Justin Kupec, Nabeeha Mohy-Ud-Din, Vipul Jairath, Francis A. Farraye, Gursimran S. Kochhar
39 [GO] 2021―Dec―09 Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments Georgios Kokkotis, Konstantina Kitsou, Ioannis Xynogalas, Vana Spoulou, Gkikas Magiorkinis, Ioannis Trontzas, et al. (+4)
40 [GO] 2021―Oct―25 Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study Cristina Bezzio, Alessandro Armuzzi, Federica Furfaro, Sandro Ardizzone, Monica Milla, Sonia Carparelli, et al. (+65)
41 [GO] 2021―Sep―26 Letter: the BSG COVID-19 interim coeliac disease guidance no-biopsy approach is safe in adults Lina Bourhan Tashtoush, Nicholas Charles Bosanko, Samuel Robin Broad, Ying Jenny Chan, Natasha Singhal, Sharon Saji, et al. (+5)
42 [GO] 2021―Sep―02 Review Article: Vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic Jayne Doherty, Sean Fennessy, Roisin Stack, Neil O’ Morain, Garret Cullen, Elizabeth J. Ryan, et al. (+2)
43 [GO] 2021―Jun―25 Editorial: IBD medications during the COVID-19 pandemic-are they safe to use? Dali Fan, Richard B. Gearry
44 [GO] 2021―Jun―10 Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study Antoine Meyer, Laura Semenzato, Mahmoud Zureik, Alain Weill, Franck Carbonnel, Rosemary Dray-Spira
45 [GO] 2020―Oct―07 Letter: population mortality from COVID-19 and latitude-data from China Nanyang Liu, Hao Li
46 [GO] 2020―Aug―31 Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission Amarylle S. van Doorn, Berrie Meijer, Chris M. A. Frampton, Murray L. Barclay, Nanne K. H. de Boer
47 [GO] 2020―Aug―15 Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19 Gianluca Ianiro, Serena Porcari, Carlo Romano Settanni, Stefano Bibbò, Francesca Romana Ponziani, Lorenzo Zileri dal Verme, et al. (+3)
48 [GO] 2020―Aug―15 Letter: online search trends suggest patient concerns around immunosuppression use in inflammatory bowel disease during COVID-19 in the United Kingdom Mohammed Nabil Quraishi, Jonathan P. Segal, Rachel Cooney, Nicholas A. Kennedy, Rachel Ainley, Naveen Sharma, et al. (+2)
49 [GO] 2020―Aug―15 Letter: role of probiotics in the COVID-19 pandemic Enrik John T. Aguila, Marie Antoinette D. C. Lontok, Eliezer James T. Aguila
50 [GO] 2020―Aug―15 Letter: role of probiotics in the COVID-19 pandemic-authors' reply Yuan Tian, Long Rong
51 [GO] 2020―Aug―15 Letter: is pneumococcal vaccination safe during the COVID-19 pandemic? Rabia Deniz, Arif Atahan Çağatay, Ahmet Gül
52 [GO] 2020―Aug―15 Letter: is pneumococcal vaccination safe during the COVID-19 pandemic? Authors’ reply Aysha H. Al-Ani, Doug Johnson, Britt Christensen
53 [GO] 2020―Aug―15 Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with coronavirus disease 2019-authors' reply Yuan Tian, Long Rong
54 [GO] 2020―Aug―15 Letter: immunotherapy in IBD patients in a SARS-CoV-2 endemic area Constanze H. Waggershauser, Cornelia Tillack-Schreiber, Christine Berchtold-Benchieb, Daniel Szokodi, Stefanie Howaldt, Thomas Ochsenkühn
55 [GO] 2020―Aug―15 Letter: immunotherapy for IBD patients in a SARS-CoV-2 endemic area-authors' reply Carlos Taxonera, Iñigo Sagastagoitia, Cristina Alba
56 [GO] 2020―Aug―10 Editorial: social distancing during the COVID-19 pandemic - IBD patients cannot stay at home forever Samantha Jane Benson-Pope, Richard B. Gearry
57 [GO] 2020―Aug―10 Editorial: social distancing during the COVID-19 pandemic-IBD patients cannot stay at home forever. Authors' reply Carlos Taxonera, Cristina Alba
58 [GO] 2020―Aug―10 Letter: IBD nurse-a pivotal role in the time of the pandemic Muhammad Umair Khan, Kamran Mushtaq, Khalid Mohsin A. A. Al-Ejji, Rafie A. Yakoob, Saad Rashid Alkaabi, Masoud Khoshnia
59 [GO] 2020―Aug―10 Letter: IBD nurse-pivotal role in the time of the pandemic. Authors’ reply Aysha H. Al-Ani, Clarissa A. Rentsch, Sofia Azim, Emma Bidgood, Princy Onasseril, Britt Christensen
60 [GO] 2020―Jul―22 The association between markers of liver injury and clinical outcomes in patients with COVID-19 in Wuhan Haijun Huang, Shanshan Chen, Hong Li, Xian-Long Zhou, Yining Dai, Wu Jia, et al. (+7)
61 [GO] 2020―Jul―13 Letter: ACE2, Rho kinase inhibition and the potential role of vitamin D against COVID-19 Giovanni Bertoldi, Lisa Gianesello, Lorenzo A. Calò
62 [GO] 2020―Jul―13 Letter: liver disease and COVID-19-not the perfect storm Rooshi Nathwani, Sujit Mukherjee, Roberta Forlano, Benjamin H. Mullish, Nikhil Vergis, Nowlan Selvapatt, et al. (+4)
63 [GO] 2020―Jul―13 Letter: liver disease and COVID-19-not the perfect storm. Authors' reply” Isabel Garrido, Rodrigo Liberal, Guilherme Macedo
64 [GO] 2020―Jul―08 Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19 Anand V. Kulkarni, Pramod Kumar, Harsh Vardhan Tevethia, Madhumita Premkumar, Juan Pablo Arab, Roberto Candia, et al. (+5)
65 [GO] 2020―Jul―06 Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2 positive patients Francesca Romana Ponziani, Fabio Del Zompo, Antonio Nesci, Francesco Santopaolo, Gianluca Ianiro, Maurizio Pompili, Antonio Gasbarrini
66 [GO] 2020―Jun―25 Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors-authors’ reply Carlos Taxonera, Iñigo Sagastagoitia, Cristina Alba, Norberto Mañas, David Olivares, Enrique Rey
67 [GO] 2020―May―20 Letter: does vitamin D have a potential role against COVID-19? Deepak Kumar, Prakamya Gupta, Dibyajyoti Banerjee
68 [GO] 2020―May―14 “Review article: COVID-19 and liver disease - what we know on 1st May 2020” Isabel Garrido, Rodrigo Liberal, Guilherme Macedo
69 [GO] 2020―May―14 Letter: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity Jose Mansur
70 [GO] 2020―May―14 Letter: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity. Authors' reply Jonathan M Rhodes, Sreedhar Subramanian, Eamon Laird, Rose Anne Kenny
71 [GO] 2020―May―14 Editorial: increasing IBD prevalence and its complications in the context of the COVID-19 pandemic Samantha Jane Benson-Pope, Richard B. Gearry
72 [GO] 2020―May―14 Editorial: increasing IBD prevalence and its complications in the context of the COVID-19 pandemic-authors' reply Dominic Stephen King, Nigel John Trudgill, Nicola J. Adderley
73 [GO] 2020―May―14 Letter: does vitamin D have a potential role against COVID-19? Authors' reply Yuan Tian, Long Rong
74 [GO] 2020―May―06 Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors Mayur Garg, Simon G Royce, John S Lubel
75 [GO] 2020―May―02 2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases Carlos Taxonera, Iñigo Sagastagoitia, Cristina Alba, Norberto Mañas, David Olivares, Enrique Rey
76 [GO] 2020―Apr―30 Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North - supports vitamin D as a factor determining severity. Authors' reply Mayur Garg, Aysha Al-Ani, Hannah Mitchell, Philip Hendy, Britt Christensen
77 [GO] 2020―Apr―29 Review Article: Prevention, Diagnosis and Management of COVID-19 in the Inflammatory Bowel Disease Patient Aysha Al-Ani, Ralley Prentice, Clarissa Rentsch, Doug Johnson, Zaid Ardalan, Neel Heerasing, et al. (+7)
78 [GO] 2020―Apr―20 Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North - supports vitamin D as a factor determining severity Jonathan M Rhodes, Sreedhar Subramanian, Eamon Laird, Rose Anne Kenny
79 [GO] 2020―Apr―14 Letter: Covid-19 and vitamin D-authors' reply Yuan Tian, Long Rong
80 [GO] 2020―Apr―13 Letter: Covid-19, and vitamin D Alba Panarese, Endrit Shahini
81 [GO] 2020―Mar―29 Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission Yuan Tian, Long Rong, Weidong Nian, Yan He
 [1] 

81 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.003 sec